Please login to the form below

Not currently logged in

FDA clears Hyperion's Ravicti for urea cycle disorders

Plans to launch in US by end of April

Hyperion Therapeutics has won approval for its urea cycle disorder (UCD) drug Ravicti in the US and says it plans to launch the product by the end of April.

Tipped as a $250m product at peak, Ravicti (glycerol phenylbutyrate) is designed to tackle the toxic effects of excess ammonia in the body and will be Hyperion's first commercialised drug.

UCD is a group of inherited rare genetic diseases that can be fatal in their most severe form if left untreated, and occur in around 1 in 10,000 births in the US.

Normally, when protein is broken down by the body it produces nitrogen as a waste product, which is removed from the blood, converted to urea and excreted in urine. In people with UCDs, nitrogen accumulates in the body as ammonia, which is highly neurotoxic.

Hyperion has been given the go-ahead by the FDA to market Ravicti for the treatment of patients aged two years or over. At the moment UCD patients are managed via protein-restricted diets, amino acid supplements and older ammonia-lowering agents such as sodium benzoate and Swedish Orphan's Buphenyl (sodium phenylbutyrate), although Hyperion claims compliance with these older drugs is poor.

Ravicti was reviewed and approved under the FDA's fast-track programme, largely on the back of a crossover study in 44 adult patients who switched between Ravicti and Buphenyl treatment.

Blood testing showed Ravicti was as effective as Buphenyl in controlling ammonia levels, while three additional studies in children and adults provided evidence supporting the long-term safety and effectiveness of Hyperion's drug.

In addition to its role in UCD, Ravicti could also have upside potential in other indications such as hepatic encephalopathy, a neurological disorder that can occur in patients with liver disease who represent a much larger patient population.

News of the approval led to a 33 per cent surge in Hyperion's share price to $21.05, well above its 52-week high of $16.48.

5th February 2013

From: Sales



COVID-19 Updates and Daily News

Featured jobs


Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

Virtual Engagement At Porterhouse: Reflections on the past few months
A look at how the pitfalls of virtual engagement can be avoided and the key advantages of virtual client and KOL engagement strategies in a now predominantly digital world....
July 2020: diversity and inclusion in clinical trials round-up
COVID-19 has continued to bring diversity and health inequality to the forefront of people’s attention. Our latest round-up covers the July news around these issues, and brings you the latest...
Medical Device Clinical Trials 2020
In July 2020, we attended and exhibited at the Medical Device Clinical Trials 2020 Virtual Experience. We really enjoyed the day and it was great to hear from like-minded people,...